DMAC (DiaMedica Therapeutics) Interest Received


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.45
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price